Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
The aim of this study is to directly compare the bone forming effects of 20 microg/day of
 teriparatide with those of 2 g/day strontium ranelate as measured by the histomorphometric
 variables and biochemical bone formation markers after 6 months of therapy in postmenopausal
 women with osteoporosis.
INCLUSION CRITERIA:

 1. Ambulatory, postmenopausal women aged 45 to 90 years inclusive at the time of entry
 into the trial, whose last menstrual period or bilateral oophorectomy occurred at
 least 5 years prior to entry into the trial. Women below the age of 55 years in whom a
 bilateral oophorectomy cannot clearly be documented must have their postmenopausal
 status confirmed by a serum FSH level greater or equal to 30 IU/L and serum estradiol
 level lower or equal to 20 pg/ml or lower or equal to 73 pmol/L.

 2. Free of severe or chronically disabling conditions other than osteoporosis.

 3. Able to use a pen-type injection delivery system satisfactorily in the opinion of the
 investigator and willing to be trained on and use the pen-injector on a daily basis.

 4. Without language barrier, cooperative, expected to return for all follow-up
 procedures, and have given informed consent after being informed of the risks,
 medications, and procedures to be used in the study.

 5. Posterior-anterior lumbar spine (L-1 through L-4) BMD and/or femoral neck BMD and/or
 total hip BMD measurement at least 2.5 standard deviations (SD) below the average bone
 mass for young women (T-score below or equal to -2.5 standard deviations). The lumbar
 spine and hip BMD assessment and the determination of the patient's eligibility for
 entry into the screening phase will be made by the individual investigator. Any lumbar
 vertebra that cannot be analyzed due to artifacts, severe crush fracture, osteophytes,
 or other abnormalities, should be excluded from the analysis. A minimum of two lumbar
 vertebrae in the L-1 through L-4 region must be evaluable by DXA if this is the only
 anatomical site where the BMD cut-off level less than -2.5 SD is demonstrated. A DXA
 assessment performed within three months prior to Visit 1 may be acceptable for
 patient's eligibility.

 6. Normal or clinically insignificant abnormal laboratory values (as defined by the
 investigator) including serum calcium, PTH(1 84), alkaline phosphatase.

 EXCLUSION CRITERIA:

 7. History of unresolved skeletal diseases that affect bone metabolism other than
 postmenopausal osteoporosis including Paget's disease, renal osteodystrophy,
 osteomalacia, any secondary causes of osteoporosis, hyperparathyroidism (uncorrected),
 and intestinal malabsorption.

 8. In the opinion of the investigator, have any medical or anatomical condition that
 potentially could put the patient at additional risk of an adverse event due to the
 biopsy procedure (for example, coagulation abnormality, anticoagulant medication,
 extreme obesity, etc).

 9. Have undergone two previous iliac bone biopsies (one in each iliac crest). Patients
 with one previous iliac bone biopsy are eligible provided that the new sample is
 obtained from the contralateral iliac crest.

 10. History of malignant neoplasms in the 5 years prior to Visit 1, with the exception of
 superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been
 definitively treated. Patients with carcinoma in situ of the uterine cervix treated
 definitively more than 1 year prior to entry into the study may be randomized.

 11. Increased baseline risk of osteosarcoma; this includes subjects with Paget's disease
 of the bone, previous primary skeletal malignancy, or skeletal exposure to therapeutic
 irradiation, i.e. prior external beam or implant radiation therapy. As an elevation of
 serum skeletal alkaline phosphatase activity may indicate the presence of Paget's
 disease, an unexplained elevation of this enzyme activity will also be exclusionary.

 12. Abnormal thyroid function not corrected by therapy. Normal thyroid function may be
 documented by a normal TSH during the screening phase or a combination of clinical and
 biochemical parameters which, in the judgment of the investigator and the Lilly
 Clinical Research Physician, sufficiently establishes the presence of normal thyroid
 function.

 13. Active liver disease or clinical jaundice.

 14. Significantly impaired renal function as defined by either of the following criteria:

 -  Serum creatinine that, in the opinion of the investigator, indicates significant
 renal impairment.

 -  Measured or calculated endogenous creatinine clearance less than 30 mL/min using
 the following Cockcroft Gault formula for creatinine clearance (ClCr) for women:

 ClCr (mL/minute) = [[(140-age) x weight (kg)]x0.85] / [72 x serum Cr (mg/dL)]

 15. Current or past treatment with any bisphosphonate, parathyroid hormone or its analogs,
 androgens or other anabolic steroids or therapeutic doses of fluorides at any time
 prior to Visit 2.

 Past treatment (more than 12 months before Visit 2) with a selective estrogen receptor
 modulator (SERM), nasal or injectable calcitonin, oral, transdermal, or injectable
 estrogens, progestins, estrogen analogs, estrogen agonists, estrogen antagonists or
 tibolone is allowed. Previous or current use of fluoridated water or topical dental
 fluoride treatments are permitted.

 16. Treatment with Vitamin D greater than 50,000 IU/week, or with any dose of calcitriol
 or Vitamin D analogs or agonists in the 6 months prior to Visit 2.

 17. Treatment with systemic corticosteroids in the last month prior to Visit 2 or for more
 than 14 days in the 1 year prior to Visit 2. Ophthalmic, otic, topical, orally
 inhaled, nasally inhaled, or intra-articular corticosteroid therapy may be used
 without these restrictions. However, orally inhaled or nasally inhaled corticosteroids
 in doses greater than 840 micrograms/day beclomethasone dipropionate or equivalent for
 more than 14 days in the last year prior to randomization will be disqualifying.